HomeCompareGILD vs NFE

GILD vs NFE: Dividend Comparison 2026

GILD yields 2.34% · NFE yields 69.30%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 NFE wins by $988.3K in total portfolio value
10 years
GILD
GILD
● Live price
2.34%
Share price
$136.34
Annual div
$3.19
5Y div CAGR
17.3%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$29.1K
Annual income
$1,614.90
Full GILD calculator →
NFE
NFE
● Live price
69.30%
Share price
$0.58
Annual div
$0.40
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$1.02M
Annual income
$265,052.56
Full NFE calculator →

Portfolio growth — GILD vs NFE

📍 NFE pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodGILDNFE
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, GILD + NFE cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
GILD pays
NFE pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

GILD
Annual income on $10K today (after 15% tax)
$198.88/yr
After 10yr DRIP, annual income (after tax)
$1,372.67/yr
NFE
Annual income on $10K today (after 15% tax)
$5,890.51/yr
After 10yr DRIP, annual income (after tax)
$225,294.68/yr
At 15% tax rate, NFE beats the other by $223,922.01/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of GILD + NFE for your $10,000?

GILD: 50%NFE: 50%
100% NFE50/50100% GILD
Portfolio after 10yr
$523.3K
Annual income
$133,333.73/yr
Blended yield
25.48%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on GILD right now

GILD
Analyst Ratings
37
Buy
20
Hold
1
Sell
Consensus: Buy
Price Target
$158.71
+16.4% upside vs current
Range: $105.00 — $180.00
Altman Z
4.1
Piotroski
8/9
NFE
Analyst Ratings
11
Buy
5
Hold
Consensus: Buy
Price Target
$15.25
+2542.1% upside vs current
Range: $4.00 — $44.00
Altman Z
-0.8
Piotroski
2/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

GILD buys
0
NFE buys
0
No recent congressional trades found for GILD or NFE in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricGILDNFE
Forward yield2.34%69.30%
Annual dividend / share$3.19$0.40
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR17.3%0%
Portfolio after 10y$29.1K$1.02M
Annual income after 10y$1,614.90$265,052.56
Total dividends collected$7.6K$865.3K
Payment frequencyquarterlyquarterly
SectorHealthcareStock
Analyst consensusBuyBuy
Analyst price target$158.71$15.25

Year-by-year: GILD vs NFE ($10,000, DRIP)

YearGILD PortfolioGILD Income/yrNFE PortfolioNFE Income/yrGap
1← crossover$10,974$274.45$17,630$6,930.01$6.7KNFE
2$12,073$330.19$30,282$11,418.32$18.2KNFE
3$13,316$398.20$50,732$18,329.76$37.4KNFE
4$14,730$481.49$82,982$28,698.82$68.3KNFE
5$16,345$583.87$132,662$43,871.51$116.3KNFE
6$18,199$710.26$207,497$65,548.42$189.3KNFE
7$20,340$866.96$317,839$95,817.08$297.5KNFE
8$22,826$1,062.22$477,256$137,168.47$454.4KNFE
9$25,731$1,306.80$703,157$192,493.00$677.4KNFE
10$29,147$1,614.90$1,017,431$265,052.56$988.3KNFE

GILD vs NFE: Complete Analysis 2026

GILDHealthcare

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of coronavirus disease 2019; and Epclusa, Harvoni, Vosevi, Vemlidy, and Viread for the treatment of liver diseases. It also offers Yescarta, Tecartus, Trodelvy, and Zydelig products for the treatment of hematology, oncology, and cell therapy patients. In addition, the company provides Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; Ranexa, an oral formulation for the treatment of chronic angina; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. Gilead Sciences, Inc. has collaboration agreements with Arcus Biosciences, Inc.; Pionyr Immunotherapeutics Inc.; Tizona Therapeutics, Inc.; Tango Therapeutics, Inc.; Jounce Therapeutics, Inc.; Galapagos NV; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Gadeta B.V.; Bristol-Myers Squibb Company; Dragonfly Therapeutics, Inc.; and Merck & Co, Inc. The company was incorporated in 1987 and is headquartered in Foster City, California.

Full GILD Calculator →

NFEStock

New Fortress Energy Inc. operates as an integrated gas-to-power infrastructure company that provides energy and development services to end-users worldwide. The company operates in two segments, Terminals and Infrastructure, and Ships. The Terminals and Infrastructure segment engages in the natural gas procurement and liquefaction; and shipping, logistics, facilities and conversion, or development of natural gas-fired power generation. The Ships segment offers floating storage and regasification units, and liquefied natural gas (LNG) carriers which are leased to customers under long-term or spot arrangements. The company operates LNG storage and regasification facility at the Port of Montego Bay, Jamaica; marine LNG storage and regasification facility in Old Harbour, Jamaica; landed micro-fuel handling facility in San Juan, Puerto Rico; marine LNG storage and regasification facility in Sergipe, Brazil; and LNG receiving facility in La Paz, Mexico, as well as Miami facility. New Fortress Energy Inc. was founded in 1998 and is based in New York, New York.

Full NFE Calculator →
📬

Get this GILD vs NFE comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

GILD vs SCHDGILD vs JEPIGILD vs OGILD vs KOGILD vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.